DXCM

SEC source: 0001093557-22-000048 · edgardoc.xml · nonDerivative · entry 1

Flynn Paul R · CIK 0001850141 · EVP Global Revenue

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,150

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 13,936 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,958 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000047 · edgardoc.xml · nonDerivative · entry 1

Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,435

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000046 · edgardoc.xml · nonDerivative · entry 1

Brown Michael Jon · CIK 0001899922 · EVP Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,038

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 12,038 unvested restricted stock units, 12,038 of which were granted on March 8, 2022 and shall vest through March 8, 2026.

SEC source: 0001093557-22-000044 · edgardoc.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · EVP Quality Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,658

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000045 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Global Medical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,045

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

SEC source: 0001093557-22-000025 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,662

F1 · shares: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 12,684 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-22-000023 · edgardoc.xml · nonDerivative · entry 1

Patterson Chad · CIK 0001850152 · EVP, Global Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,528

F1 · shares: On June 14, 2021, Mr. Patterson adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Patterson. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 12,528 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,394 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 575 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-22-000020 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,370

F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-22-000018 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,617

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 15

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 3,000

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F13 · price: This transaction was executed in multiple trades at prices ranging from $451.96 to $452.94. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 14

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 3,400

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F12 · price: This transaction was executed in multiple trades at prices ranging from $450.96 to $451.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 13

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 3,600

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F11 · price: This transaction was executed in multiple trades at prices ranging from $449.61 to $450.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 12

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 3,800

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F10 · price: This transaction was executed in multiple trades at prices ranging from $448.53 to $449.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 11

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 4,200

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F9 · price: This transaction was executed in multiple trades at prices ranging from $447.06 to $447.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 10

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 4,400

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F8 · price: his transaction was executed in multiple trades at prices ranging from $445.54 to $446.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 9

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 4,600

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F7 · price: This transaction was executed in multiple trades at prices ranging from $444.35 to $445.05. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 8

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 5,000

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F6 · price: This transaction was executed in multiple trades at prices ranging from $442.93 to $443.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 7

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 5,443

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $434.28 to $434.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 6

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 6,590

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F4 · price: his transaction was executed in multiple trades at prices ranging from $441.69 to $442.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 5

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,066

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $440.65 to $441.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 4

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,266

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 3

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,366

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 2

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,466

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000016 · edgardoc.xml · nonDerivative · entry 1

KAHN BARBARA · CIK 0001520391 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 7,566

F1 · shares: On November 12, 2021, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan.

F2 · balance_after: Represents 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.

SEC source: 0001093557-22-000005 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,620

F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-22-000002 · edgardoc.xml · nonDerivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,617

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-22-000002 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,291

F3 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2019 that vested on January 18, 2022, with the applicable performance achieved.

F3 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2019 that vested on January 18, 2022, with the applicable performance achieved.

F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-22-000002 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,705

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000295 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,870

F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000292 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,247

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

F2 · balance_after: Included in this number are 20,426 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000291 · edgardoc.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,217

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

F2 · balance_after: Included in this number are 12,684 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000290 · edgardoc.xml · nonDerivative · entry 1

Flynn Paul R · CIK 0001850141 · EVP, Global Revenue

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,853

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

F2 · balance_after: Included in this number are 13,853 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 1,378 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000288 · edgardoc.xml · nonDerivative · entry 1

Patterson Chad · CIK 0001850152 · EVP, Global Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,528

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

F2 · balance_after: Included in this number are 12,528 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,394 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 575 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000287 · edgardoc.xml · nonDerivative · entry 1

Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,461

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

F2 · balance_after: Included in this number are 13,461 unvested restricted stock units, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

SEC source: 0001093557-21-000286 · edgardoc.xml · nonDerivative · entry 1

Regan Barry J. · CIK 0001746313 · EVP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,128

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

F2 · balance_after: Included in this number are 13,128 unvested restricted stock units, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 14

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,705

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 13

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,755

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 12

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,805

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F12 · price: This transaction was executed in multiple trades at prices ranging from $541.06 to $541.785. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 11

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,005

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F11 · price: This transaction was executed in multiple trades at prices ranging from $539.96 to $540.94. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 10

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,205

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F10 · price: This transaction was executed in multiple trades at prices ranging from $538.74 to $539.56. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 9

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,384

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F9 · price: This transaction was executed in multiple trades at prices ranging from $537.59 to $538.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 8

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,911

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F8 · price: This transaction was executed in multiple trades at prices ranging from $536.53 to $537.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 7

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,182

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F7 · price: This transaction was executed in multiple trades at prices ranging from $535.47 to $536.395. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 6

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,432

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F6 · price: This transaction was executed in multiple trades at prices ranging from $534.32 to $535.14. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 5

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,932

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 4

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,032

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $531.45 to $532.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,332

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,357

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $529.35 to $530.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000279 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,505

F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $527.75 to $528.59. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

SEC source: 0001093557-21-000276 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,120

F1 · shares: The transaction represents a gift by the Reporting Person of 5,459 shares to a charitable donor advised fund.

F2 · balance_after: Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022.